tailieunhanh - báo cáo hóa học:" Clinical Translation Section: Accelerating the Pace from Bench to Bedside"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học đề tài : Clinical Translation Section: Accelerating the Pace from Bench to Bedside | Kandalaft and Coukos Journal of Translational Medicine 2011 9 116 http content 9 1 116 JOURNAL OF TRANSLATIONAL MEDICINE EDITORIAL Open Access Clinical Translation Section Accelerating the Pace from Bench to Bedside Lana E Kandalaft and George Coukos Editorial Cell and gene therapy clinical trials have been conducted for various indications such as cancer cardiovascular diseases and autoimmune disorders for more than 20 years. The increased understanding of immune function cancer biology and stem cell biology have dramatically accelerated the development of technology for cell and gene therapy in these areas. Supported by some successful clinical results the development of many potential new technologies has produced an explosion of therapeutic pursuits in the clinic. The new technologies have produced significant challenges in the clinical translation space including the need to develop innovative clinical trial designs to accelerate development of therapies by minimizing the number of patients required to evaluate safety and efficacy to develop and incorporate methods to capture important biologic effects of cell and or gene based therapies in patients and to dissect the impact of therapeutic combinations. Furthermore the increasingly personalized flavor of cell and gene therapies has produced an ever-greater need for developing reliable biomarkers for selecting patients and measuring biologic effects of therapy. Finally regulatory agencies have recognized the need for modifying acceptable evaluation metrics to respond to the increasing complexity in clinical design and interventions. Yet despite significant advancement in the field progress remains slow relative to discovery and the need of speeding up clinical application of basic science discoveries is still unmet. Indeed the rapid advancement of therapeutic technologies in the laboratory the plethora of biomarker candidates and the recent innovations in clinical science .